225 related articles for article (PubMed ID: 17121897)
1. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
Redjal N; Chan JA; Segal RA; Kung AL
Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
[TBL] [Abstract][Full Text] [Related]
2. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
[TBL] [Abstract][Full Text] [Related]
5. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
6. Use of verapamil to enhance the antiproliferative activity of BCNU in human glioma cells: an in vitro and in vivo study.
Bowles AP; Pantazis CG; Wansley W
J Neurosurg; 1990 Aug; 73(2):248-53. PubMed ID: 2366081
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of TNP-470 in combination with BCNU on tumor growth of human glioblastoma xenografts.
Yao D; Zhao H; Zhang F; Chen J; Jiang X; Zhu X
J Huazhong Univ Sci Technolog Med Sci; 2010 Dec; 30(6):757-61. PubMed ID: 21181367
[TBL] [Abstract][Full Text] [Related]
8. Profound blockage of CXCR4 signaling at multiple points using the synergy between plerixafor, mirtazapine, and clotrimazole as a new glioblastoma treatment adjunct.
Kast RE
Turk Neurosurg; 2010 Oct; 20(4):425-9. PubMed ID: 20963689
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy.
Branle F; Lefranc F; Camby I; Jeuken J; Geurts-Moespot A; Sprenger S; Sweep F; Kiss R; Salmon I
Cancer; 2002 Aug; 95(3):641-55. PubMed ID: 12209758
[TBL] [Abstract][Full Text] [Related]
10. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of genistein and BCNU on growth inhibition and cytotoxicity of glioblastoma cells.
Khoshyomn S; Nathan D; Manske GC; Osler TM; Penar PL
J Neurooncol; 2002 May; 57(3):193-200. PubMed ID: 12125982
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study of combination therapy against human glioma xenograft by differentiation-inducing agent and cytotoxic chemotherapeutic drug].
Shi MG; Huang Q; Dong J; Sun ZF; Lan Q
Ai Zheng; 2002 Oct; 21(10):1090-4. PubMed ID: 12508650
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo.
Chakrabarti M; Ray SK
Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275
[TBL] [Abstract][Full Text] [Related]
14. Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Levin VA; Wara WM; Davis RL; Vestnys P; Resser KJ; Yatsko K; Nutik S; Gutin PH; Wilson CB
J Neurosurg; 1985 Aug; 63(2):218-23. PubMed ID: 2991486
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy of BCNU and Didox acts synergystically in 9L glioma cells.
Horvath Z; Bauer W; Hoechtl T; Saiko P; Fritzer-Szekeres M; Tihan T; Szekeres T
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1531-5. PubMed ID: 15571292
[TBL] [Abstract][Full Text] [Related]
16. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Plowman J; Waud WR; Koutsoukos AD; Rubinstein LV; Moore TD; Grever MR
Cancer Res; 1994 Jul; 54(14):3793-9. PubMed ID: 8033099
[TBL] [Abstract][Full Text] [Related]
19. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.
Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul M
Clin Cancer Res; 2001 Mar; 7(3):634-40. PubMed ID: 11297259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
